National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Lung Cancer

Lung cancer grows in tissues of the lung, usually in the cells that line the air passages. There are two main types of lung cancer: small cell and non-small cell.

Small cell lung cancer: About 13 percent of lung cancers are small cell lung cancers. This cancer often starts in the bronchi near the center of the chest. Although the cancer cells are small, they can multiply quickly and form large tumors that can spread throughout the body.

Non-small cell lung cancer: Most lung cancers (about 87 percent) are non-small cell lung cancers. This cancer spreads more slowly than small cell lung cancer. There are several types of non-small cell lung cancer. The cancer cells of each type grow and spread in the body in different ways.

  • Adenocarcinoma is usually found in the outer part of the lung; it accounts for about 40 percent of all lung cancers
  • Squamous cell carcinoma tends to be found in the middle of the lungs, near a bronchus (airway); it accounts for 25–30 percent of all lung cancers
  • Large cell carcinoma can start in any part of the lung and tends to grow and spread quickly, which makes it harder to treat; it accounts for 10–15 percent of lung cancers

It is estimated that 228,190* people in the United States will be newly diagnosed with lung cancer in 2013.

Treatment options for lung cancer vary depending on the type of lung cancer, stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Lung Cancer Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with lung cancer. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Lung Cancer
Phase II
Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
NCI-12-C-0151, NCT01624090

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
NCI-11-C-0096, NCT01306045

Principal Investigator:Referral Contact:
Udayan GuhaArlene Berman
301-402-3524301-435-5609
arleneb@mail.nih.gov
Randomized Phase II Study of AZD6244 (Mitogen-Activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Advanced NSCLC
NCI-10-C-0218, NCT01229150

Principal Investigator:Referral Contact:
Arun RajanCorrine Keen
301-594-5322301-496-3778
ckeen@mail.nih.gov
Phase I/II
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
NCI-10-C-0138, NCT01143545

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov
Phase I
Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum
NCI-11-C-0111, NCT01313429

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov
No Phase
Prospective Evaluation of Epigenetic Alterations in Patients With Thoracic Malignancies
NCI-06-C-0014, NCT00447447

Principal Investigator:Referral Contact:
David S. SchrumpTricia Kunst
301-496-2128301-451-1233
tricia_kunst@nih.gov


  
Trial and Protocol Number
Solid Tumor
Phase II
Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
NCI-12-C-0199, NCT01679743

Principal Investigator:Referral Contact:
Susan BatesChristine Bryla
301-402-5958301-451-7868
brylacm@mail.nih.gov
A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
NCI-09-C-0214, NCT00978250

Principal Investigator:Referral Contact:
James H. DoroshowJanelle Bingham
301-496-4291301-435-2715
jbingham@mail.nih.gov
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
NCI-08-C-0121, NCT00670748

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I/II
Phase I/II Study of Metastatic Cancer that Expresses MAGE-A3/12 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
NCI-11-C-0062, NCT01273181

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
Phase I
A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C, a Monoclonal Anti-PD-L1 Antibody, in Adults With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
NCI-13-C-0063, NCT01772004

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression
NCI-13-C-0016, NCT01730118

Principal Investigator:Referral Contact:
Lauren V. WoodBrenda Roberson
301-402-0199301-435-4733
broberson@mail.nih.gov
An Open Label Phase I Study to Evaluate the Safety and Tolerability of GI-6301 Vaccine Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express Brachyury Protein in Adults With Solid Tumors
NCI-12-C-0056, NCT01519817

Principal Investigator:Referral Contact:
James L. GulleyLaura D. Otten
301-435-2956301-451-1228
1-866-611-6310 (Toll Free)
ottenl@mail.nih.gov
Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
NCI-11-C-0061, NCT01273168

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors
NCI-10-C-0113, NCT01120288

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
NCI-09-C-0173, NCT00926640

Principal Investigator:Referral Contact:
Susan BatesChristine Bryla
301-402-5958301-451-7868
brylacm@mail.nih.gov
Phase 0
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
NCI-11-C-0212, NCT01413451

Principal Investigator:Referral Contact:
Raffit HassanYvonne Mallory
301-451-8742301-402-0255
malloryy@mail.nih.gov
No Phase
A Natural History Study of Patients Receiving High Dose Rate Brachytherapy
NCI-09-C-0100, NCT00924027

Principal Investigator:Referral Contact:
Aradhana KaushalSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov